Corneal Cross-Linking for Brittle Cornea Syndrome.

Abstract

PURPOSE:

To describe corneal cross-linking (CXL) as a treatment option for brittle cornea syndrome (BCS).

METHODS:

Case report.

RESULTS:

Ethical decision making enabled bilateral sequential transepithelial CXL in an 11-year-old girl with BCS. Postoperative courses were uneventful with a bilateral stromal demarcation line, unchanged corneal transparency, constant endothelial cell density, and stable topography 2 years after intervention.

CONCLUSIONS:

Modified CXL can safely be performed in patients with BCS. Ethical review may be helpful for interventions deviating from standard practice.

• Authors: Claude Kaufmann, Gregor Schubiger, Michael A Thiel
• Journal: Cornea (Cornea) Vol. 34 Issue 10 Pg. 1326-8 (Oct 2015) ISSN: 1536-4798 [Electronic] United States
• PMID: 26266434 (Publication Type: Case Reports, Journal Article)

Chemical References

• Cross-Linking Reagents
• DNA-Binding Proteins
• PRDM5 protein, human
• Photosensitizing Agents
• Transcription Factors
• Collagen
• Riboflavin

Topics

• Child
• Collagen (metabolism)
• Corneal Stroma (metabolism)
• Cross-Linking Reagents
• DNA-Binding Proteins (genetics)
• Eye Abnormalities (drug therapy, genetics, metabolism)
• Female
• Humans
• Joint Instability (congenital, drug therapy, genetics, metabolism)
• Mutation
• Photosensitizing Agents (therapeutic use)
• Riboflavin (therapeutic use)
• Skin Abnormalities (drug therapy, genetics, metabolism)
• Transcription Factors (genetics)
• Ultraviolet Rays
• Visual Acuity